Northern Trust Corp Buys 65,335 Shares of Chimerix, Inc. (CMRX)
Northern Trust Corp increased its stake in shares of Chimerix, Inc. (NASDAQ:CMRX) by 10.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 696,440 shares of the biopharmaceutical company’s stock after purchasing an additional 65,335 shares during the quarter. Northern Trust Corp owned approximately 1.49% of Chimerix worth $3,795,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. American International Group Inc. increased its position in Chimerix by 7.1% during the 1st quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 1,733 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Chimerix during the 2nd quarter worth about $185,000. Metropolitan Life Insurance Co. NY purchased a new stake in Chimerix during the 1st quarter worth about $226,000. Alps Advisors Inc. increased its position in Chimerix by 5.5% during the 2nd quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 2,178 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Chimerix by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 3,300 shares in the last quarter. Hedge funds and other institutional investors own 69.46% of the company’s stock.
WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/22/northern-trust-corp-buys-65335-shares-of-chimerix-inc-cmrx.html.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. The company had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. analysts expect that Chimerix, Inc. will post -1.6 EPS for the current fiscal year.
A number of analysts recently commented on CMRX shares. ValuEngine cut Chimerix from a “sell” rating to a “strong sell” rating in a research report on Monday, September 18th. Zacks Investment Research cut Chimerix from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX).
Receive News & Stock Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related stocks with our FREE daily email newsletter.